Loading
A phase 1/2 trial of Purinostat in multiple myeloma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06484829 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 144 participants planned, started 2024-03-25 and due to reach its primary completion in 2026-02-01. Interventions recorded: Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2 and Purinostat Mesylate 8.4 mg/m2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/